AKT1 and acute lymphoblastic leukemia: Our group recently reported the synergistic effect of RAD001, in both Ph− B-ALL cell lines and patient samples, with MK-2206, a specific, potent and orally bioavailable allosteric Akt inhibitor that targets both its catalytic and PH domains [180].